ERBB2 and cancer: In vivo studies showed that the combination of IP administration and the use of targeted HBc particles (99mTc-ZHER2-ΔHBc) resulted in significantly enhanced tumour accumulation in the intraperitoneal tumour model, suggesting selective uptake of ZHER2-ΔHBc particles in HER2 (+++) tumours in vivo. Findings from this work offer fundamental knowledge on the biodistribution of newly reported recombinant HBc particles designed for local delivery of nucleic acids to intraperitoneal cancer.